Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Earnings for Generation Bio Co. (GBIO)
Earnings in 2023 (TTM): $-126,612,000
According to Generation Bio Co.'s latest financial reports the company's current earnings (TTM) are $-126,612,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Generation Bio Co.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-126,612,000 | $-126,612,000 |
| 2022 | $-136,639,000 | $-132,096,000 |
| 2021 | $-119,151,000 | $-114,669,000 |
| 2020 | $-80,523,000 | $-76,500,000 |
| 2019 | $-61,317,000 | $-60,332,000 |
| 2018 | $-35,803,000 | $-35,803,000 |